FrancophonIA/ELRC3.0 huggingface dataset:
English: In studies 312-0116/0117 and 312-0119, rash (reported as dermatitis exfoliative generalised, drug eruption, rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, papule and skin plaque) occurred in 31.1% of subjects who received idelalisib + an anti-CD20 monoclonal antibody (rituximab or ofatumumab) and 8.2% who received an anti-CD20 monoclonal antibody only (rituximab or ofatumumab).
Slovenian: V študijah 312-0116/0117 in 312-0119 se je izpuščaj (o njem so poročali kot o generaliziranem eksfoliativnem dermatitisu, medikamentnem izpuščaju, izpuščaju, eritematoznem izpuščaju, generaliziranem izpuščaju, makularnem izpuščaju, makulopapularnem izpuščaju, papularnem izpuščaju, pruritičnem izpuščaju, pustularnem izpuščaju, vezikularnem izpuščaju, papulah in kožnem plaku) pojavil pri 31,1 % oseb, ki so prejemale idelalizib + monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab), in pri 8,2 % oseb, ki so prejemale samo monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab).
English: Therefore, caution is recommended when administering Zydelig in this population and an intensified monitoring of adverse reactions is recommended (see sections 4.4 and 5.2).
Slovenian: Zato se pri dajanju zdravila Zydelig tej populaciji priporoča previdnost in intenzivnejše spremljanje neželenih učinkov (glejte poglavji 4.4 in 5.2).
English: Of these, 5.7% who received idelalisib + an anti-CD20 monoclonal antibody (rituximab or ofatumumab) and 1.5% who received an anti-CD20 monoclonal antibody only (rituximab or ofatumumab) had rash of Grade 3, and no subjects had an adverse reaction of Grade 4.
Slovenian: Od teh je imelo 5,7 % oseb, ki so prejemale idelalizib + monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab), in 1,5 % oseb, ki so prejemale samo monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab), izpuščaj 3. stopnje, nobena oseba pa ni imela neželenega učinka 4. stopnje.
English: Idelalisib exposure may be reduced when co-administered with CYP3A inducers such as rifampicin, phenytoin, St. John's wort (Hypericum perforatum), or carbamazepine.
Slovenian: Izpostavljenost idelalizibu se lahko zmanjša pri sočasni uporabi z induktorji CYP3A, kot so rifampicin, fenitoin, šentjanževka (Hypericum perforatum) ali karbamazepin.
English: • clarithromycin, telithromycin, medicines used to treat bacterial infections
Slovenian: • klaritromicin, telitromicin, zdravili, ki se uporabljata za zdravljenje bakterijskih okužb
English: Zydelig is a cancer medicine that contains the active substance idelalisib.
Slovenian: Zdravilo Zydelig je zdravilo proti raku, ki vsebuje učinkovino idelalizib.
English: Serious and fatal infections have occurred with idelalisib, including opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP) and cytomegalovirus (CMV).
Slovenian: Pri idelalizibu so se pojavile resne in smrtne okužbe, vključno z oportunističnimi okužbami, kot sta pljučnica, ki jo povzroča Pneumocystis jirovecii (PJP), in okužba s citomegalovirusom (CMV).
English: A dose-related increase in pancreatic islet cell tumors was observed at low incidence in male rats at exposures up to 0.4-fold compared to the human exposure at the recommended dose; a similar finding was not observed in female rats at 0.62-fold exposure margin.
Slovenian: Pri samcih podgan so ob 0,4-kratni izpostavljenosti v primerjavi s človeško izpostavljenostjo pri priporočenem odmerku opazili od odmerka odvisno povečanje tumorjev celic pankreasnih otočkov z majhno incidenco; pri samicah podgan pri 0,62-kratni meji izpostavljenosti podobnega učinka niso opazili.
English: Breast-feeding It is not known whether idelalisib and its metabolites are excreted in human milk.
Slovenian: Dojenje Ni znano, ali se idelalizib in njegovi presnovki izločajo v materino mleko.
English: Take care to not miss a dose of Zydelig.
Slovenian: Bodite skrbni in odmerkov zdravila Zydelig ne izpustite.
English: • quetiapine, a medicine used to treat schizophrenia, bipolar disorder and major depressive disorder
Slovenian: • kvetiapin; zdravilo, ki se uporablja za zdravljenje shizofrenije, bipolarne motnje in velike depresivne motnje
English: 20.9 (20.9, NR)
Slovenian: 20,9 (20,9; ND)
English: Idelalisib is a selective inhibitor of adenosine-5'-triphosphate (ATP) binding to the catalytic domain of PI3Kδ, resulting in inhibition of the phosphorylation of the key lipid second messenger phosphatidylinositol and prevention of Akt (protein kinase B) phosphorylation.
Slovenian: Idelalizib je selektivni zaviralec adenozin 5'-trifosfata (ATP), ki se veže na katalitično domeno PI3Kδ, kar povzroči zaviranje fosforilacije fosfatidilinozitola, glavnega lipidnega sekundarnega obveščevalca, in prepreči fosforilacijo Akt (proteinske kinaze B).
English: The recommended dose is 150 mg by mouth twice a day.
Slovenian: Priporočeni odmerek je 150 mg dvakrat na dan peroralno.
English: Since a reduction in idelalisib plasma concentrations may result in decreased efficacy, co-administration of Zydelig with moderate or strong CYP3A inducers should be avoided (see section 4.5).
Slovenian: Ker lahko zmanjšanje koncentracij idelaliziba v plazmi zmanjša učinkovitost, se je treba sočasnemu dajanju zdravila Zydelig z zmernimi ali močnimi induktorji CYP3A izogniti (glejte poglavje 4.5).
English: Through inhibition of chemokine receptors CXCR4 and CXCR5 signalling induced by the chemokines CXCL12 and CXCL13, respectively, idelalisib inhibits homing and retention of malignant B-cells in the tumour microenvironment including lymphoid tissues and the bone marrow.
Slovenian: Z zaviranjem prenosa signalov hemokinskih receptorjev CXCR4 in CXCR5, ki jih povzročita hemokina CXCL12 oz. CXCL13, idelalizib zavira zadrževanje in zastoj malignih celic B v mikrookolju tumorja, vključno z limfnimi tkivi in kostnim mozgom.
English: Idelalisib + R 110 (0) 101 (3) 93 (7) 73 (9) 59 (14) 31 (19) 20 (21) 9 (24) 7 (24) 4 (24) 1 (25) 0 (25) Placebo + R 110 (0) 84 (21) 48 (38) 29 (46) 20 (53) 9 (63) 4 (67) 1 (69) 0 (70) 0 (70) 0 (70) 0 (70)
Slovenian: Idelalizib + R 110 (0) 101 (3) 93 (7) 73 (9) 59 (14) 31 (19) 20 (21) 9 (24) 7 (24) 4 (24) 1 (25) 0 (25) Placebo + R 110 (0) 84 (21) 48 (38) 29 (46) 20 (53) 9 (63) 4 (67) 1 (69) 0 (70) 0 (70) 0 (70) 0 (70)
English: Caution is advised if Zydelig is used together with narrow therapeutic index drugs that are substrates of CYP2C8 (paclitaxel).
Slovenian: Previdnost se svetuje pri uporabi zdravila Zydelig skupaj z zdravili z ozkim terapevtskim indeksom, ki so substrati CYP2C8 (paklitaksel).
English: In an embryo-foetal development study in rats, increased post-implantation loss, malformations (absence of caudal vertebrae and in some cases also of sacral vertebrae), skeletal variations and lower foetal body weights were observed.
Slovenian: V študiji razvoja zarodka in ploda pri podganah so opazili večjo izgubo po ugnezditvi, deformacije (odsotnost repnih vretenc in v nekaterih primerih tudi križnih vretenc), spremembe v razvoju okostja in nižjo telesno maso zarodkov.
English: It is not known whether the active substance in Zydelig passes into human milk.
Slovenian: Ni znano, ali se učinkovina zdravila Zydelig izloča v materino mleko.
English: Idelalisib inhibits phosphatidylinositol 3-kinase p110δ (PI3Kδ), which is hyperactive in B-cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing, and retention of malignant cells in lymphoid tissues and bone marrow.
Slovenian: Idelalizib zavira fosfatidilinozitol 3-kinazo p110δ (PI3Kδ), ki je pri malignostih B-celic hiperaktivna in osrednjega pomena za več poti prenosa signalov, ki so gonilo proliferacije, preživetja, zadrževanja in zastoja malignih celic v limfnih tkivih in kostnem mozgu.
English: Stevens-Johnson syndrome/ toxic epidermal necrolysis
Slovenian: Stevens-Johnsonov sindrom/ toksična epidermalna nekroliza redki redki
English: Idelalisib did not induce mutations in the microbial mutagenesis (Ames) assay, was not clastogenic in the in vitro chromosome aberration assay using human peripheral blood lymphocytes, and was not genotoxic in the in vivo rat micronucleus study.
Slovenian: Idelalizib v testih mutageneze na mikrobih (Amesov test) ni povzročil mutacij, v testu kromosomskih aberacij in vitro pri človeških limfocitih periferne krvi ni bil klastogen in v študiji s podganjimi mikronukleusi in vivo ni bil genotoksičen.
English: • sildenafil, tadalafil, medicines used to treat impotence and pulmonary hypertension, a lung disease that makes breathing difficult
Slovenian: • sildenafil, tadalafil, zdravili, ki se uporabljata za zdravljenje impotence in pljučne hipertenzije - bolezni pljuč, ki otežuje dihanje
English: Following a single 150 mg oral dose of [14C]-labelled idelalisib, approximately 78% and 15% was excreted in faeces and urine, respectively.
Slovenian: Po peroralnem dajanju enega 150 mg odmerka s [14C] označenega idelaliziba se ga je približno 78 % izločilo v blatu in približno 15 % v urinu.
English: • ciclosporin, sirolimus, tacrolimus, medicines used to control your body's immune response after a transplant
Slovenian: • ciklosporin, sirolimus, takrolimus, zdravila za nadzor imunskega odziva telesa po presaditvi
English: Blood counts should be monitored in all patients at least every 2 weeks for the first 6 months of treatment with idelalisib, and at least weekly in patients while ANC is less than 1,000 per mm3 (see section 4.2).
Slovenian: Pri vseh bolnikih je treba prvih 6 mesecev zdravljenja z idelalizibom najmanj vsaka 2 tedna spremljati krvno sliko, pri bolnikih z ANC pod 1.000 na mm3 pa najmanj enkrat tedensko (glejte poglavje 4.2).
English: For patients with evidence of CMV viraemia and clinical signs of CMV infection, consideration should be given to interrupting idelalisib until the infection has resolved.
Slovenian: Pri bolnikih z znaki viremije CMV in kliničnimi znaki okužbe s CMV je treba razmisliti o prekinitvi zdravljenja z idelalizibom, dokler okužba ne izgine.
English: Its primary metabolite is GS-563117, which is not pharmacologically active.
Slovenian: Njegov primarni presnovek je GS-563117, ki ni farmakološko aktiven.
English: Serum transaminase elevations correlated with hepatic necrosis in dogs, but were not observed in rats.
Slovenian: Povečanje transaminaze v serumu je bilo pri psih soodvisno od jetrne nekroze, pri podganah pa tega niso opazili.
English: Stevens-Johnson syndrome and toxic epidermal necrolysis Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with fatal outcomes have been reported when idelalisib was administered concomitantly with other medicinal products associated with these syndromes.
Slovenian: Stevens-Johnsonov sindrom in toksična epidermalna nekroliza Poročali so o Stevens-Johnsonovem sindromu (SJS) in toksični epidermalni nekrolizi (TEN) s smrtnimi izidi, ko so idelalizib dajali sočasno z drugimi zdravili, povezanimi s tema sindromoma.
English: Among the 122 subjects with measurable lymph nodes at both baseline and post-baseline, 71 subjects (58.2%) achieved a ≥ 50% decrease from baseline in the sum of the products of the diameters (SPD) of index lesions.
Slovenian: Med 122 osebami z merljivimi bezgavkami ob izhodišču in po izhodišču je 71 oseb (58,2 %) doseglo ≥ 50-odstotno zmanjšanje od izhodišča glede na vsoto zmnožkov premerov (SPD) indikacijskih lezij.
English: Caution is advised if Zydelig is used together with narrow therapeutic index drugs that are substrates of these enzymes (warfarin, phenytoin, S-mephenytoin).
Slovenian: Previdnost se svetuje pri uporabi zdravila Zydelig skupaj z zdravili z ozkim terapevtskim indeksom, ki so substrati teh encimov (varfarin, fenitoin, S-mefenitoin).
English: GS-563117 is not an inhibitor of the metabolising enzymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or UGT1A1, or of the transporters P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.
Slovenian: GS-563117 ni zaviralec presnovnih encimov CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali UGT1A1 ali prenašalcev P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3 ali OCT2.
English: Monitor ANC at least weekly until ANC ≥ 500/mm3, then may resume Zydelig dosing at 100 mg twice daily.
Slovenian: ANC spremljajte najmanj enkrat tedensko, dokler ni ANC ≥ 500/mm3, nato lahko nadaljujete z odmerjanjem zdravila Zydelig 100 mg dvakrat dnevno.
English: Following 150 mg twice daily administration of idelalisib, average (range) Cmax and AUC at steady-state were 1,953 (272; 3,905) ng/mL and 10,439 (2,349; 29,315) ng•h/mL for idelalisib and 4,039 (669; 10,897) ng/mL and 39,744 (6,002; 119,770) ng•h/mL for GS-563117, respectively.
Slovenian: Po odmerjanju idelaliziba 150 mg dvakrat na dan sta bila povprečna (razpon) Cmax in AUC v stanju dinamičnega ravnovesja 1.953 (272; 3.905) ng/ml in 10.439 (2.349; 29.315) ng•h/ml za idelalizib oz. 4.039 (669; 10.897) ng/ml in 39.744 (6.002; 119.770) ng•h/ml za GS-563117.
English: The first infusion of ofatumumab was administered at a dose of 300 mg and was continued at a dose of either 1,000 mg in the idelalisib + ofatumumab group or a dose of 2,000 mg in the ofatumumab only group, weekly for 7 doses, and then every 4 weeks for 4 doses.
Slovenian: Prvo infundiranje ofatumumaba je vključevalo odmerek 300 mg in se je nadaljevalo s 7 tedenskimi odmerki 1.000 mg v skupini z idelalizibom + ofatumumabom ali 2.000 mg v skupini, ki je prejemala samo ofatumumab, nato pa s 4 odmerki vsake 4 tedne.
English: Caution should be exercised when administering Zydelig in patients with active hepatitis.
Slovenian: Pri dajanju zdravila Zydelig bolnikom z aktivnim hepatitisom je potrebna previdnost.
English: In addition, 86 subjects from this study who were randomised to receive placebo + rituximab went on to receive idelalisib as a single agent in an extension study (study 312-0117).
Slovenian: Poleg tega je 86 oseb iz te študije, ki so bili randomizirani za prejemanje placeba + rituksimaba, v podaljšani študiji (študija 312-0117) nadaljevalo s prejemanjem samostojnega idelaliziba.
English: Stevens-Johnson syndrome and toxic epidermal necrolysis (see section 4.4) Rarely, cases of SJS and TEN have occurred when idelalisib was administered concomitantly with other medicinal products associated with these syndromes (bendamustine, rituximab, allopurinol, and amoxicillin).
Slovenian: Stevens-Johnsonov sindrom in toksična epidermalna nekroliza (glejte poglavje 4.4) Redko so poročali o primerih SJS in TEN, ko so idelalizib dajali sočasno z drugimi zdravili, povezanimi s tema sindromoma (bendamustin, rituksimab, alopurinol in amoksicilin).
English: If a patient misses a dose by more than 6 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
Slovenian: Če bolnik izpusti odmerek za več kot 6 ur, naj bolnik ne nadomesti izpuščenega odmerka in nadaljuje z jemanjem po običajnem režimu odmerjanja.
English: Subjects received idelalisib 150 mg twice daily and rituximab 375 mg/m2 BSA weekly for 8 doses.
Slovenian: Osebe so prejemale idelalizib 150 mg dvakrat na dan in 8 tedenskih odmerkov rituksimaba 375 mg/m2 BSA.
English: ENDOTHELIN RECEPTOR ANTAGONISTS
Slovenian: ANTAGONISTI RECEPTORJEV ENDOTELINA bosentan
English: How to take Zydelig
Slovenian: Kako jemati zdravilo Zydelig
English: Idelalisib should not be co-administered with midazolam (oral) or triazolam.
Slovenian: Idelaliziba se ne sme dati sočasno z midazolamom (peroralnim) ali triazolamom.
English: The Kaplan-Meier curve for PFS is provided in Figure 1.
Slovenian: KaplanMeierjeva krivulja za PFS je na sliki 1.
English: Relative to fasting conditions, administration of an early capsule formulation of idelalisib with a highfat meal resulted in no change in Cmax and a 36% increase in mean AUCinf.
Slovenian: V primerjavi s pogoji na tešče dajanje zgodnje oblike kapsule idelaliziba z obrokom z visoko vsebnostjo maščob ni povzročilo spremembe vrednosti Cmax, povprečna vrednost AUCinf pa se je povečala za 36 %.
English: Therefore, women of childbearing potential must use highly effective contraception while taking Zydelig and for 1 month after stopping treatment.
Slovenian: Zato morajo ženske v rodni dobi med jemanjem zdravila Zydelig in še 1 mesec po prenehanju zdravljenja uporabljati zelo učinkovito kontracepcijo.
English: Idelalisib in combination with ofatumumab
Slovenian: Idelalizib v kombinaciji z ofatumumabom
English: Based on findings in animals, idelalisib may cause foetal harm.
Slovenian: Na podlagi izsledkov pri živalih lahko idelalizib škoduje plodu.
English: In general, B-lymphocyte dependent areas were more affected than T-lymphocyte dependent areas.
Slovenian: Na splošno so bili predeli, odvisni od limfocitov B, bolj prizadeti, kot predeli,
English: The primary and only circulating metabolite, GS-563117, is inactive against PI3Kδ.
Slovenian: Njegov primarni in edini cirkulirajoči presnovek, GS-563117, je proti PI3Kδ neaktiven.
English: There are no or limited amount of data from the use of idelalisib in pregnant women.
Slovenian: Podatkov o uporabi idelaliziba pri nosečnicah ni oziroma so omejeni.
English: Effect of idelalisib on the pharmacokinetics of other medicinal products
Slovenian: Učinek idelaliziba na farmakokinetiko drugih zdravil
English: Table 2: Adverse drug reactions reported in clinical studies in subjects with haematologic malignancies receiving idelalisib
Slovenian: Preglednica 2: Neželeni učinki zdravila, o katerih so poročali v kliničnih študijah pri osebah s hematološkimi malignostmi, ki so dobivali idelalizib Neželeni učinek
English: ANC should be monitored at least weekly until ANC is ≥ 500 per mm3 when treatment can be resumed at 100 mg twice daily (see section 4.4).
Slovenian: ANC je treba spremljati najmanj enkrat tedensko, dokler ni ANC ≥ 500 na mm3, nato se zdravljenje lahko nadaljuje s 100 mg dvakrat dnevno (glejte poglavje 4.4).
English: Fentanyl, alfentanil, methadone, buprenorphine/naloxone
Slovenian: fentanil, alfentanil, metadon, buprenorfin/nalokson
English: Effect of other medicinal products on idelalisib pharmacokinetics
Slovenian: Učinek drugih zdravil na farmakokinetiko idelaliziba
English: Following a single 150 mg dose, idelalisib AUC (total, i.e., bound plus unbound) was ~60% higher in moderate and severe impairment compared to matched controls.
Slovenian: Po enem 150 mg odmerku je bila vrednost AUC za idelalizib (skupni, tj. vezan in nevezan) ~60 % višja pri zmerni in hudi okvari v primerjavi z ustrezno kontrolno skupino.
English: Co-administration of Zydelig with moderate or strong CYP3A inducers such as rifampicin, phenytoin, St. John's wort, or carbamazepine should be avoided as this may result in decreased efficacy (see section 4.4).
Slovenian: Sočasnemu dajanju zdravila Zydelig z zmernimi ali močnimi induktorji CYP3A, kot so rifampicin, fenitoin, šentjanževka ali karbamazepin, se je treba izogniti, saj lahko to zmanjša učinkovitost (glejte poglavje 4.4).
English: Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from available data).
Slovenian: Pogostnosti so opredeljene kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do
English: Zydelig can cause severe diarrhoea.
Slovenian: Zdravilo Zydelig lahko povzroči hudo drisko.
English: Boceprevir, telaprevir
Slovenian: Zaviralci proteaze HCV boceprevir, telaprevir
English: Idelalisib and GS-563117 are substrates of P-gp and BCRP.
Slovenian: Idelalizib in GS-563117 sta substrata P-gp in BCRP.
English: Ergotamine, dihydroergotamine ↑ serum concentrations Idelalisib should not be co-administered with ergotamine or dihydroergotamine.
Slovenian: ERGOT ALKALOIDI ergotamin, dihidroergotamin ↑ koncentracij v serumu Idelaliziba se ne sme dati sočasno z ergotaminom ali dihidroergotaminom.
English: Treatment with Zydelig must be withheld in the event of Grade 3 or 4 ALT/AST elevation and liver function monitored.
Slovenian: Zdravljenje z zdravilom Zydelig je treba prekiniti v primeru povečanja ravni ALT/AST 3. in 4. stopnje ter opazovati funkcijo jeter.
English: Zydelig can cause lung inflammation.
Slovenian: Zdravilo Zydelig lahko povzroči vnetje pljuč.
English: You should take additional medicine provided by your doctor while you are taking Zydelig to prevent one type of infection.
Slovenian: Medtem ko jemljete zdravilo Zydelig, morate jemati tudi dodatno zdravilo, ki vam ga predpiše zdravnik, da preprečite okužbo.
English: Table 1: Interactions between idelalisib and other medicinal products that are CYP3A substrates
Slovenian: Preglednica 1: Medsebojna delovanja med idelalizibom in drugimi zdravili, ki so substrati
English: If the event recurs, treatment with Zydelig must be withheld until the values return to Grade 1 or less, after which re-initiation at 100 mg twice daily may be considered at the discretion of the physician (see sections 4.4 and 4.8).
Slovenian: Če se dogodek ponovi, je treba zdravljenje z zdravilom Zydelig začasno ustaviti, dokler se vrednosti ne vrnejo na 1. ali nižjo stopnjo, nato naj se po presoji zdravnika nadaljuje z jemanjem 100 mg dvakrat na dan (glejte poglavji 4.4 in 4.8).
English: ↑ serum concentrations Careful monitoring of the tolerance to these anti-cancer agents is recommended.
Slovenian: ↑ koncentracij v serumu Priporoča se skrbno spremljanje prenašanja teh zdravil proti raku.
English: Serious and fatal infections have occurred in patients taking Zydelig.
Slovenian: Pri bolnikih, ki so jemali zdravilo Zydelig, so se pojavile resne in smrtne okužbe.
English: Clinical monitoring is recommended for patients with CrCl < 90 mL/min.
Slovenian: Pri bolnikih s CrCl < 90 ml/min se priporoča klinično spremljanje.
English: ↑ serum concentrations Dose reductions of colchicine may be required.
Slovenian: ↑ koncentracij v serumu Morda bo treba odmerek kolhicina zmanjšati.
English: • if you have redness and blistering of the skin
Slovenian: • če imate pordelo ali mehurjasto kožo,
English: A clinical drug interaction study found that co-administration of idelalisib with midazolam (a sensitive CYP3A substrate) resulted in a ~140% increase in Cmax and a ~440% increase in AUCinf of midazolam due to the CYP3A inhibition by GS-563117.
Slovenian: V klinični študiji medsebojnega delovanja zdravil so ugotovili, da je sočasno dajanje idelaliziba z midazolamom (občutljiv substrat CYP3A) povzročilo ~140-odstotno povečanje Cmax in ~440-odstotno povečanje AUCinf midazolama, ker GS-563117 zavira CYP3A.
English: Medicinal product
Slovenian: FARMACEVTSKI PODATKI
English: CYP3A/P-gp inhibitors
Slovenian: Zaviralci CYP3A/P-gp
English: Once values have returned to Grade 1 or below (ALT/AST ≤ 3 x ULN), treatment can be resumed at 100 mg twice daily.
Slovenian: Ko se vrednosti vrnejo na 1. ali nižjo stopnjo (ALT/AST ≤ 3 x ULN), se lahko zdravljenje nadaljuje z odmerkom 100 mg dvakrat na dan.
English: *** Includes the preferred terms dermatitis exfoliative generalised, drug eruption, rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, papule, skin plaque, and exfoliative rash.
Slovenian: *** Vključuje prednostne izraze generalizirani eksfoliativni dermatitis, medikamentni izpuščaj, izpuščaj, eritematozni izpuščaj, generalizirani izpuščaj, makularni izpuščaj, makulopapularni izpuščaj, papularni izpuščaj, pruritični izpuščaj, pustularni izpuščaj, vezikularni izpuščaj, papule, kožni plak in eksfoliativni izpuščaj.
English: A clinical drug interaction study found that co-administration of a single dose of 400 mg idelalisib with 400 mg once daily ketoconazole (a strong CYP3A, P-gp and BCRP inhibitor) resulted in a 26% increase in Cmax and a 79% increase in AUCinf of idelalisib.
Slovenian: V klinični študiji medsebojnega delovanja zdravil so ugotovili, da je sočasno dajanje enega odmerka 400 mg idelaliziba s ketokonazolom 400 mg enkrat na dan (močan zaviralec CYP3A, P-gp in BCRP) povzročilo 26-odstotno zmanjšanje Cmax in 79-odstotno povečanje AUCinf idelaliziba.